Skip to content
OpenCapital
Get started

Innovate VATE Life Sciences — Cost of revenue

Other segment segments

Infrastructure
$307M+37.4%
Spectrum
$2.9M0.0%

Other financials

Income statement

See full
Revenue$364.8M+33.0%
Gross profit$53.5M+17.6%
Operating income$10.0M+194%
Net income-$16.8M+31.4%
EPS (diluted)-$1.29+31.7%

Balance sheet

See full
Cash & equivalents$134.6M+297%
Total debt$1.4B+11.6%
Total equity-$256.3M-25.5%
Total assets$936.8M+7.9%

Cash flow

See full
Operating cash flow$45.5M+423%
CapEx$200.0K-95.7%
Free cash flow$45.3M+341%

Valuation

See full
Market cap$254.69M+274%

Where this comes from

Reported directly by Innovate in its filing.

Tagged under the XBRL concept us-gaap:CostOfRevenue.

The official record: Innovate’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Innovate's life sciences — cost of revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Innovate's life sciences — cost of revenue?
Innovate (VATE) reported life sciences — cost of revenue of $1.4M in Q1 2026.
How has Innovate's life sciences — cost of revenue changed year-over-year?
Innovate's life sciences — cost of revenue decreased by 39.1% year-over-year, from $2.3M to $1.4M.
What is the long-term trend for Innovate's life sciences — cost of revenue?
Over 2 years (2023 to 2025), Innovate's life sciences — cost of revenue has grown at a 79.7% compound annual growth rate (CAGR), from $2.6M to $8.4M.
What does life sciences — cost of revenue mean?
This metric encompasses the direct costs attributable to the production and delivery of goods or services sold by the Life Sciences segment. It is a fundamental measure of the segment's operational efficiency and gross margin performance.